/images/ppid_59c68470-image-176976258909882386.webp)
/images/ppid_a911dc6a-image-176976102852922851.webp)
/images/ppid_a911dc6a-image-176976102974610137.webp)
/images/ppid_a911dc6a-image-176976106847853386.webp)
What is the story about?
Dr Lal PathLabs on Friday, January 30, reported a mixed set of numbers for the December quarter.
Net profit fell 6.4% year-on-year to ₹90.5 crore in Q3, compared with ₹96.7 crore in the same period last year.
Revenue, however, rose 10.8% to ₹660 crore from ₹595.7 crore.
Operating performance remained strong during the quarter, with EBITDA climbing 17.3% year-on-year to ₹179 crore from ₹152.7 crore.
As a result, EBITDA margin expanded to 27.1%, compared with 25.6% a year ago.
Following the earnings announcement, shares of Dr Lal PathLabs Ltd. were trading 0.13% higher at
₹
1,397.
Net profit fell 6.4% year-on-year to ₹90.5 crore in Q3, compared with ₹96.7 crore in the same period last year.
Revenue, however, rose 10.8% to ₹660 crore from ₹595.7 crore.
Operating performance remained strong during the quarter, with EBITDA climbing 17.3% year-on-year to ₹179 crore from ₹152.7 crore.
As a result, EBITDA margin expanded to 27.1%, compared with 25.6% a year ago.
Following the earnings announcement, shares of Dr Lal PathLabs Ltd. were trading 0.13% higher at
